Cannabidiol (CBD) has attracted a lot of attention from scientists as a therapy for conditions such as epilepsy, anxiety, arthritis and other inflammatory diseases. This video explores the biochemistry, pharmacology and synthetic organic chemistry of novel cannibidiol-molecules.

CBD: 0:52
CB2 Receptor: 3:07
Assays used: 5:05
Results: 8:24
Synthesis: 13:50

Published by:
Gemma Navarro, Angel Gonzalez, Adrià Sánchez-Morales, Nil Casajuana-Martin, Marc Gómez-Ventura, Arnau Cordomí, Félix Busqué, Ramon Alibés*, Leonardo Pardo*, and Rafael Franco*

J. Med. Chem. 2021, 64, 13, 9354–9364. ‘Design of Negative and Positive Allosteric Modulators of the Cannabinoid CB2 Receptor Derived from the Natural Product Cannabidiol’

Socials:
https://www.patreon.com/SimplifyingSynthesis
https://www.instagram.com/simplifyingsynthesis/
Twitter: @SimplifyingSyn1
https://www.facebook.com/SimplifyingSynthesis

References:
J. Med. Chem. 2021, 64, 13, 9354–9364 (This work)
J. Clin.Pharmacol. 2019, 59, 923−934. (CBD Review)
Neurotherapeutics 2015, 12, 699−730. (CBD Targets)
Nature. 1997, 386, 247–253 (cAMP Regulation)
Cell, 2020, 180, 645–654 (CB2R Structure)
Nature Communications, 2018, 9, 3712 (Stabilizing Antibody)
Pharmacological Research. 2012,66, 105– 143 (ERK1/2 Function)
Nature Protocols. 2011,  6, pages 1748–1760 (DMR Assay)
Eur. J. Org. Chem. 2015, 7460–7467 (Demethylation Mechanism)
ACS Med. Chem. Lett. 2016, 7, 424– 428 (Friedel-Crafts Reaction)
Green Chem. 2019, 21, 2621– 2628 (Debromination Reaction)